INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (1, 47, 'CNS Tumors');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (2, 48, 'Head & Neck Malignancies');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (3, 49, 'Anal Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (4, 50, 'Colon and Rectal Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (5, 51, 'Esophegeal Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (6, 52, 'Gastric Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (8, 54, 'Gastrointestinal Stromal Tumor (GIST)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (9, 55, 'Biliary Tract Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (10, 55, 'Hepatocellular Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (11, 56, 'Pancreatic Cancer');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (12, 57, 'Non-Small Cell');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (13, 58, 'Small Cell');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (14, 59, 'Thymoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (15, 60, 'HER-2 Neu Negative');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (16, 61, 'HER-2 Neu Positive');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (17, 62, 'Hormonal Therapy');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (18, 63, 'Cervical');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (19, 64, 'Endometrial');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (20, 65, 'Ovarian');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (21, 66, 'Bladder');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (22, 67, 'Kidney');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (23, 68, 'Harmone-Refractory');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (24, 68, 'Hormonal');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (25, 69, 'Testicular');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (26, 70, 'Sarcoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (27, 71, 'Kaposi''s Sarcoma- AIDS Related');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (28, 72, 'Unknown Primary');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (29, 73, 'AIDS-Related');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (30, 74, 'Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (31, 75, 'Non-Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (32, 76, 'Acute Lymphocytic Leukemia (ALL)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (33, 77, 'Acute Myeloid Leukemia (AML)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (34, 78, 'Chronic Lymphocytic Leukemia (CLL)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (35, 79, 'Chronic Myeloid Leukemia (CML)');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (36, 80, 'Hairy Cell Leukemia');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (37, 81, 'Myeloma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (38, 82, 'CNS Tumors');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (39, 83, 'Neuroblastoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (40, 84, 'Retinoblastoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (41, 85, 'Hepatoblastoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (42, 86, 'Wilms'' Tumor');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (43, 87, 'Osteosarcoma');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (44, 88, 'Soft tissue and Bone');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (45, 89, 'Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (46, 90, 'Non-Hodgkin''s');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (47, 91, 'Acute Lymphocytic Leukemia');
INSERT INTO SubCancerType2 (pk, SubCancerTypeId1, title) VALUES (48, 92, 'Acute Myeloid Leukemia');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (47, 1, 'CNS Tumors');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (48, 2, 'Head & Neck Malignancies');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (49, 3, 'Anal Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (50, 3, 'Colon and Rectal Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (51, 3, 'Esophegeal Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (52, 3, 'Gastric Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (54, 3, 'Gastrointestinal Stromal Tumor (GIST)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (55, 3, 'Hepatobiliary');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (56, 3, 'Pancreatic Cancer');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (57, 4, 'Non-Small Cell');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (58, 4, 'Small Cell');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (59, 4, 'Thymoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (60, 5, 'HER-2 Neu Negative');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (61, 5, 'HER-2 Neu Positive');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (62, 5, 'Hormonal Therapy');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (63, 6, 'Cervical');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (64, 6, 'Endometrial');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (65, 6, 'Ovarian');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (66, 7, 'Bladder');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (67, 7, 'Kidney');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (68, 7, 'Prostate');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (69, 7, 'Testicular');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (70, 8, 'Sarcoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (71, 9, 'Kaposi''s Sarcoma- AIDS Related');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (72, 10, 'Unknown Primary');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (73, 11, 'AIDS-Related');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (74, 11, 'Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (75, 11, 'Non-Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (76, 12, 'Acute Lymphocytic Leukemia (ALL)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (77, 12, 'Acute Myeloid Leukemia (AML)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (78, 12, 'Chronic Lymphocytic Leukemia (CLL)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (79, 12, 'Chronic Myeloid Leukemia (CML)');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (80, 12, 'Hairy Cell Leukemia');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (81, 13, 'Myeloma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (82, 14, 'CNS Tumors');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (83, 15, 'Neuroblastoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (84, 16, 'Retinoblastoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (85, 17, 'Hepatoblastoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (86, 18, 'Wilms'' Tumor');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (87, 19, 'Osteosarcoma');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (88, 19, 'Soft tissue and Bone');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (89, 20, 'Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (90, 20, 'Non-Hodgkin''s');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (91, 21, 'Acute Lymphocytic Leukemia');
INSERT INTO SubCancerType1 (pk, CancerTypeId, title) VALUES (92, 21, 'Acute Myeloid Leukemia');
INSERT INTO PatientType (pk, title) VALUES (1, 'Adult');
INSERT INTO PatientType (pk, title) VALUES (2, 'Pediatric');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (1, 1, 'CNS Tumors');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (2, 1, 'Head & Neck Malignancies');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (3, 1, 'Gastro Intestinal');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (4, 1, 'Thoracic');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (5, 1, 'Breast Cancer');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (6, 1, 'Gynecologic Malignancy');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (7, 1, 'Urinary Tract');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (8, 1, 'Sarcoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (9, 1, 'Kaposi''s Sarcoma- AIDS Related');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (10, 1, 'Unknown Primary');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (11, 1, 'Lymphoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (12, 1, 'Leukemia');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (13, 1, 'Myeloma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (14, 2, 'CNS Tumors');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (15, 2, 'Neuroblastoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (16, 2, 'Retinoblastoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (17, 2, 'Hepatoblastoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (18, 2, 'Wilms'' Tumor');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (19, 2, 'Sarcoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (20, 2, 'Lymphoma');
INSERT INTO CancerType (pk, PatientTypeId, title) VALUES (21, 2, 'Leukemias');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (1, 1, 'Bevacizumab/Irinotecan', '<b>Bevacizumab/Irinotecan</b>', '<b>Bevacizumab</b> 15 mg/kg IV<br> Repeat Every 21 Days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> with enzyme-inducing antiepileptic drugs, days 1, 8, 22, 29<br> <b>OR</b><br> <b>Irinotecan</b> 125 mg/m<sup>2</sup> with non-enzyme-including antiepileptic drugs, IV, days 1, 8, 22, 29<br> Repeat every 6 weeks', 'Moderate', 'Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. $J Clin Oncol. 2007;25(30):4722-4279.$', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (2, 1, 'PCV', '<b>PCV</b>', '<b>Procarbazine</b> 60 mg/m<sup>2</sup>/d PO, days 8-21<br> <b>Lomustine</b> 110 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, days 8, 29<br> Repeat every 6 weeks upto 7 cycles ', 'Moderate-High', 'Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N'' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. $Clin Cancer Res.2000;6(10):3878-3884.$', '<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>', 'Lomustine : CCNU<br>Procarbazine : Matulane<br>Vincristine : Oncovin, VCR');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (3, 1, 'Temozolomide+RT', '<b>Temozolomide+RT</b>', '<b>Temozolomide</b> 75 mg/m<sup>2</sup> daily along with radiation<br> <b>FOLLOWED 28 DAYS LATER BY</b><br><b>Temozolomide<sup>e</sup></b> 150 mg/m<sup>2</sup> daily for 5 days<br>Repeat every 28 days.', 'Moderate for IV<br> <=75 mg/m<sup>2</sup> PO is minimal-low;<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', 'Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.$N Engl J Med 2005; 352:987-996$', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Temozolomide : Temodar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (4, 1, 'BCNU (Carmustine)', '<b>BCNU (Carmustine)</b>', '<b>Carmustine</b> 200 mg/m<sup>2</sup> IV over 30-60 minutes<br> Repeat every 8 weeks ', 'High', 'Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine. $Neurosurgery.2002;51(2):343-355; discussion 355-357.$', '<b>Hepatic Impairment</b><ul><li>Carmustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carmustine:<br>If CrCl < 60 mL/min, do not use</li></ul>', 'Carmustine : BCNU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (5, 1, 'Bevacizumab', '<b>Bevacizumab</b>', '<b>Bevacizumab</b> 10 mg/kg IV<br> Repeat every 14 days on a 28-day cycle<br><b>OR</b><br><b>Bevacizumab</b> 15 mg/kg IV<br> Repeat every 21 days ', 'Low', 'Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma. $J Clin Oncol. 2009;27(5):740-745.$                                                           Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas. $Cancer.2010;116(22):597-5305.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (6, 1, 'Temozolomide', '<b>Temozolomide</b>', '<b>Temozolomide</b> 150 mg/m<sup>2</sup> every day for 5 days per 28-day cycle<br> ', 'Moderate for IV<br> >75 mg/m<sup>2</sup> PO is moderate-high   ', 'Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.$J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27$', '<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>', 'Temozolomide : Temodar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (7, 2, 'Carboplatin/Fluorouracil/Cetuximab', '<b>Carboplatin/Fluorouracil/Cetuximab</b>', '<b>Carboplatin</b> AUC of 5, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1 <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week.', 'Moderate', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', '<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Carboplatin : Paraplatin<br>Cetuximab : Erbitux<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (8, 2, 'CF', '<b>CF</b>', '<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>5-Fluorouracil</b> 1000 mg/m<sup>2</sup>/day CIVI, days 1-4<br> Repeat every 21 days', 'High', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (9, 2, 'Cisplatin/Fluorouracil/Cetuximab', '<b>Cisplatin/Fluorouracil/Cetuximab</b>', '<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximuum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1. <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week', 'High', 'Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. $N Engl J Med. 2008;359(11):1116-1127.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cetuximab : Erbitux<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (10, 2, 'Cisplatin + radiation', '<b>Cisplatin + radiation</b>', '<b>Cisplatin</b> 75 mg/m<sup>2</sup>  IV, days 1,22, 43 concomitantly with radiation', 'High', 'Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma. $Cancer. 2009;115(11):2464-2471.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (11, 2, 'CP', '<b>CP</b>', '<b>Cisplatin</b> 75 mg/m<sup>2</sup>, day 1 and<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours on day 1<br> Repeat cycle every 21 days', 'High', 'Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. $J Clin Oncol. 2005;23(15):3562-3567.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (12, 2, 'TPF', '<b>TPF</b>', '<b>Docetaxel<sup>b</sup></b> 75mg/m<sup>2</sup> IV over 1 hour, day1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Fluorouraacil</b> 750 mg/m<sup>2</sup>/d, days 1-5<br> Repeat every 21 days<br> <b>OR</b><br> <b>Docetaxel<sup>b</sup></b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for 3 cycles', 'High', 'Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. $N Engl J Med. 2007;357(17):1695-1704.$<br> Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. $N Engl J Med. 2007;357(17):1705-1715.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (13, 2, 'Cetuximab', '<b>Cetuximab</b>', '<b>Cetuximab</b> 400 mg/m<sup>2</sup> loading dose over 120 minutes, <b>THEN</b> 250 mg/m<sup>2</sup> over 60 minutes, every 7 days', 'Low', 'Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival. $Lancet Oncol.2010;11(1):21-28.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Cetuximab : Erbitux');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (14, 5, '5-Fluorouracil + Cisplatin', '<b>5-Fluorouracil + Cisplatin</b>', '<b>5-Fluorouracil</b>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5<br><b>Cisplatin</b>100 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle on weeks 1, 5, 8, and 11.', 'High', '$Kies MS, et al. Cancer 1987;60:2156-2160.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (15, 5, 'Irinotecan + Cisplatin', '<b>Irinotecan + Cisplatin</b>', '<b>Irinotecan</b>65 mg/m<sup>2</sup> IV weekly for 4 weeks<br><b>Cisplatin</b>30 mg/m<sup>2</sup> IV weekly for 4 weeks<br>Repeat cycle every 6 weeks.', 'High', '$Ilson DH, et al. J Clin Oncol 1999;17:3270-3275.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (16, 5, 'Paclitaxel + Cisplatin', '<b>Paclitaxel + Cisplatin</b>', '<b>Paclitaxel</b>200 mg/m<sup>2</sup> IV over 24 hours on day 1<br><b>Cisplatin</b>75 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 21 days. G-CSF support is recommended.', 'High', '$Ilson DH, et al. J Clin Oncol 1998;16:1826-1834.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Cisplatin : CDDP<br>Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (17, 5, 'Capecitabine + Oxaliplatin', '<b>Capecitabine + Oxaliplatin</b>', '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every 21 days.', 'Moderate', '$Van Meerten E, et al. Br J Cancer 2007;96:1348-1352.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (18, 5, 'ECF', '<b>ECF</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks.<br>Repeat cycle every 21 days.', 'High', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (19, 5, 'EOF', '<b>EOF</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks<br>Repeat cycle every 21 days.', 'Moderate', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (20, 5, 'ECX', '<b>ECX</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid continuously<br>Repeat cycle every 21 days.', 'High', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (21, 5, 'EOX', '<b>EOX</b>', '<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid times 21 days<br>Repeat cycle every 21 days.', 'Moderate', '$Cunningham D, et al. N Engl J Med 2008;358:36-46.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (22, 5, 'Paclitaxel', '<b>Paclitaxel</b>', '<b>Paclitaxel</b>250 mg/m<sup>2</sup> IV over 24 hours on day 1<br>Repeat cycle every 21 days. G-CSF support is recommended.', 'Moderate', '$Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40.$', '<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>', 'Paclitaxel : Taxol');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (23, 6, 'DCF', '<b>DCF</b>', '<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1-3 hours, day 1<br> <b>Fluorouracil</b> 750 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 21 days', 'High', 'Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. $J Clin Oncol. 2006;24(31):4991-4997$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (24, 6, 'Docetaxel/Cisplatin', '<b>Docetaxel/Cisplatin</b>', '<b>Docetaxel</b> 85 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> Repeat every 21 days for a maximum of 8 cycles', 'High', 'Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. $Ann Oncol. 2000;11(3):301-306$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (25, 6, 'ECF', '<b>ECF</b>', '<b>Epirubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 200 mg/m<sup>2</sup>/d CIVI, for up to 6 months<br> Repeat every 21 days for a maximum of 8 cycles', 'High', 'Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. $Br J Cancer. 1999;80(1-2):269-272.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP<br>Epirubicin : Ellence, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (26, 6, 'ELF', '<b>ELF</b>', '<b>Leucovorin calcium</b> 300 mg/m<sup>2</sup>/d IV over 10 minutes, <b>FOLLOWED BY</b><br> <b>Etoposide</b> 120 mg/m<sup>2</sup>/d IV over 50 minutes,<br> <b>THEN</b><br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV  bolus<br> Give all agents on days 1-3; repeat every 22 days', 'Low', 'Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group. $J Clin Oncol. 2000;18(41):2648-2657$', '<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Etoposide : VP-16<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (27, 6, '5-FU/LV and Radiation', '<b>5-FU/LV and Radiation</b>', '<b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days,<br> <b>FOLLOWED BY</b><br> <b>RT</b> 4,500 cGy (180cGy/d), 5 days a week for 5 weeks<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup>/d IV, on the first 4 and last 3 days of RT<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d, on the first 4 and last 3 days of RT,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days<br>repeat 28 days X 2 cycles', 'Low', 'Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. $N Engl J Med. 2001;345(10):725-730.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (28, 6, 'Trastuzumab + Cisplatin + Capecitabine or Fluorouracil', '<b>Trastuzumab + Cisplatin + Capecitabine or Fluorouracil</b>', '<b>Trastuzumab</b> 8 mg/kg IV, day 1 of the first cycle <b>THEN</b>  6 mg/kg IV, day 1<br><br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1. <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14 <br> Repeat  every 21 days<br> <b>OR</b><br> <b>Fluorouracil</b> 800 mg/m<sup>2</sup>/d CIVI for 5 days of each 3-week cycle<br> Repeat for 6 cycles', 'High day 1, low for the remaining treatment days', 'Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial. $Lancet. 2010;376(99742):687-697.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Cisplatin : CDDP<br>Fluorouracil : 5-FU<br>Trastuzumab : Herceptin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (29, 6, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> days 1-14,  <br> Repeat every 21 days for  6 cycles', 'Low', 'Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. $Ann Oncol. 2004;15(9):1344-1347.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (30, 6, 'Epirubicin + Oxaliplatin + Capecitabine (EOX)', '<b>Epirubicin + Oxaliplatin + Capecitabine (EOX)</b>', '<b>Epirubicin</b> 50 mg/m2 IV bolus d1 q3w x 8 cycles<br>
<b>Oxaliplatin</b> 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles<br>
<b>Capecitabine</b> 625 mg/m2 po bid x 6 months.', 'High', 'Cunningham D et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. $N Eng J Med 2008; 358:36.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Epirubicin : Ellence, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (31, 10, 'GEMOX', '<b>GEMOX</b>', '<b>Gemcitabine</b>1,000 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>100 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 2 weeks.', 'Moderate', '$Taieb J, et al. Cancer 2003;98:2664-2670.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (32, 10, 'FOLFOX4', '<b>FOLFOX4', '<b>Oxaliplatin</b>85 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>400 mg/m<sup>2</sup> IV bolus, followed by 600 mg/m<sup>2</sup> IV continuous infusio for 22 hours on days 1 and 2<br><b>Leucovorin</b>200 mg/m<sup>2</sup> IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil<br>Repeat cycle every 2 weeks.', 'Moderate', '$Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408).$', '<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (33, 10, 'Bevacizumab + Erlotinib', '<b>Bevacizumab + Erlotinib</b>', '<b>Bevacizumab</b>10 mg/kg IV on days 1 and 14<br><b>Erlotinib</b>150 mg PO daily<br>Repeat cycle every 28 days.', 'Low', '$Thomas MB, et al. J Clin Oncol 2009;27:843-850.$', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin<br>Erlotinib : Tarceva');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (34, 10, 'Sorafenib', '<b>Sorafenib</b>', '<b>Sorafenib</b>400 mg PO bid.', 'Low', '$Llovet J, et al. N Engl J Med 2008;359:378-390.$', '<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>', 'Sorafenib : Nexavar');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (35, 10, 'Doxorubicin', '<b>Doxorubicin</b>', '<b>Doxorubicin</b>20-30 mg/m<sup>2</sup> IV weekly<br>Repeat cycle every week.', 'Moderate', '$Venook AP. J Clin Oncol 1994;12:1323-1334.$', '<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>', 'Doxorubicin : Adriamycin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (36, 10, 'Cisplatin', '<b>Cisplatin</b>', '<b>Cisplatin</b>80 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every week.', 'High', '$Okada S, et al. Oncology 1993;50:22-26.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (37, 10, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br>Repeat cycle every 21 days. PO bid on days 1-14.', 'Moderate', '$Patt YZ, et al. Cancer 2004;101:578-586.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (38, 10, 'Bevacizumab', '<b>Bevacizumab</b>', '<b>Bevacizumab</b>10 mg/kg IV on day 1<br>Repeat cycle every 14 days.', 'Low', '$Siegel AB, et al. J Clin Oncol 2008;26:2992-2998.$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', 'Bevacizumab : Avastin');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (39, 9, 'Gemcitabine + Cisplatin', '<b>Gemcitabine + Cisplatin</b>', '<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV on Day 1<br> Repeat cycle every 21 days', 'Low', '$Thongprasert S, et al. Ann Oncol 2005;16:279-281$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Cisplatin : CDDP<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (40, 9, 'Gemcitabine + Capecitabine', '<b>Gemcitabine + Capecitabine</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO BID on Days 1-14<br> Repeat cycle every 21 days', 'Moderate', '$Knox JJ, et al. J Clin Oncol 2005;23:2332-2338.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (41, 9, 'Gemcitabine + Oxaliplatin', '<b>Gemcitabine + Oxaliplatin</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup> on Day 2<br> Repeat cycle every 14 days', 'Moderate', '$Andre T, et al. Ann Oncol 2004;15:1339-1343.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (42, 9, '5-Fluorouracil + Cisplatin', '<b>5-Fluorouracil + Cisplatin</b>', '<b>5-FU</b> 400 mg/m<sup>2</sup> on Day 1<br> <b>FOLLOWED BY</b> 600 mg/m<sup>2</sup> continuous infusion over 22 hours on days 1 and 2<br> <b>Cisplatin</b> 50 mg /m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', 'High', '$Taieb J, et al. Ann Oncol 2002;13:1192-1196.$', '<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (43, 9, 'Capecitabine + Cisplatin', '<b>Capecitabine + Cisplatin</b>', '<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days', 'High', '$Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>', 'Capecitabine : Xeloda<br>Cisplatin : CDDP');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (44, 9, 'Capecitabine + Oxaliplatin', '<b>Capecitabine + Oxaliplatin</b>', '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', 'Moderate', '$Nehis O, et al. Br J Cancer 2008;98:309-315.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Capecitabine : Xeloda<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (45, 9, 'Capecitabine', '<b>Capecitabine</b>', '<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> Repeat cycle every 21 days', 'Moderate', '$Patt YZ, et al. Cancer 2004;101:578-586.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>', 'Capecitabine : Xeloda');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (46, 9, 'Docetaxel', '<b>Docetaxel</b>', '<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days', 'Moderate', '$Papakostas P, et al. Eur J Cancer 2001;37:1833-1838.$', '<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>', 'Docetaxel : Taxotere');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (47, 9, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on days 1 and 8<br> Repeat cycle every 21 days', 'Moderate', '$Park JS, et al. Jpn J Clin Oncol 2005;35:68-73.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (48, 11, 'FOLFIRINOX', '<b>FOLFIRINOX</b>', '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours <b>FOLLOWED BY Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours with the addition, after 30 minutes <b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes; <b>IMMEDIATELY FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>THEN</b><br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> IV over 46 hours<br> Repeat cycle every 2 weeks', 'Moderate', 'Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. $N Engl J Med. 2011;364(19):1817-1825.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (49, 11, 'Gemcitabine/Capecitabine', '<b>Gemcitabine/Capecitabine</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days.', 'Low', 'Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. $J Clin Oncol. 2007;25(16):221-2217.$', '<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Capecitabine : Xeloda<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (50, 11, 'Gemcitabine/Erlotinib', '<b>Gemcitabine/Erlotinib</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> <b>Erlotinib</b> 100 <b>OR</b> 150 mg/d PO<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', 'Low', 'Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group. $J Clin Oncol. 2007;25(15):1960-1966.$', '<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Erlotinib : Tarceva<br>Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (51, 11, 'GEMOX', '<b>GEMOX</b>', '<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>, day 1 as 100-minute infusion<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup>, day 2 as 2-hour infusion<br> Repeat every 14 days', 'Moderate', 'Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. $J Clin Oncol. 2005;23(15):3509-3516.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Gemcitabine : Gemzar, various<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (52, 11, 'Gemcitabine', '<b>Gemcitabine</b>', '<b>Gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks', 'Low', 'Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. $J Clin Oncol. 1997;15(6):2403-2413.$', '<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>', 'Gemcitabine : Gemzar, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (53, 4, 'Cetuximab/Irinotecan', '<b>Cetuximab/Irinotecan</b>', '<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose,<b>THEN</b> 250 mg/m<sup>2</sup> IV every 7 days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV every 21 days<br> <b>OR</b> 180 mg/m<sup>2</sup> IV every 14 days', 'Moderate', 'Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. $N Engl J Med. 2004;351(4):337-345.$', '<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cetuximab : Erbitux');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (54, 4, '5-FU/LV (Mayo regimen)', '<b>5-FU/LV (Mayo regimen)</b>', '<b>Fluorouracil</b> 370mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1-5<br> <b>FOLLOWING Leucovorin calcium</b> 200 mg/m<sup>2</sup>/d IV bolus, days 1-5<br> Repeat at 4 and 8 weeks, and every 5 weeks thereafter', 'Low ', 'Poon MA, O''Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma. $J Clin Oncol. 1989;7(10):1407-1418$', '<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (55, 4, '5-FU/LV (Roswell Park regimen)', '<b>5-FU/LV (Roswell Park regimen)</b>', '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks', 'Low', 'Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. $J Clin Oncol. 1989;7(10):1419-1426$<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma. $J Clin Oncol. 1987;5(10):1559-1565.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (56, 4, '5-FU/LV + Bevacizumab', '<b>5-FU/LV + Bevacizumab</b>', '<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks<br> <b>Bevacizumab</b> 5mg/kg IV<br> Repeat every 14 days', 'Low', 'Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer. $J Clin Oncol. 2005;23(16):3706-3712.$<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer. $J Clin Oncol. 2005;23(15):3502-3508$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (57, 4, 'FLOX', '<b>FLOX</b>', '<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours, days 1, 15, 29<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV bolus 1 hour after the infusion begins, days 1, 8, 15, 22,    29, 36<br> Repeat every 8 weeks for 3 cycles', 'Moderate', 'Kuebler JP, Wieand HS, O''Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. $J Clin Oncol. 2007;25(16):2198-2204.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (58, 4, 'FOLFIRI', '<b>FOLFIRI</b>', '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days', 'Moderate', 'Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. $J Clin Oncol. 2004;22(2):229-237$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (59, 4, 'FOLFIRI + Bevacizumab', '<b>FOLFIRI + Bevacizumab</b>', '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours, day 1<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours, day 1<br> <b>Bevacizumab</b> 5 mg/kg IV, day 1<br> Repeat every 14 days', 'Moderate', 'Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. $J Clin Oncol. 2007;25(30):4779-4786.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (60, 4, 'FOLFIRI + Cetuximab', '<b>FOLFIRI + Cetuximab</b>', '<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THERE AFTER</b> 250mg/m<sup>2</sup> IV weekly', 'Moderate', 'Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. $J Clin Oncol. 2007;25:4000 (abstract).$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>', 'Cetuximab : Erbitux<br>Fluorouracil : 5-FU');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (61, 4, 'FOLFOX4', '<b>FOLFOX4</b>', '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV AND <br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br><b>Day 2</b><br><b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days', 'Moderate', 'Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.$http://jco.ascopubs.org/content/24/25/4085.abstract$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (62, 4, 'FOLFOX4 + Bevacizumab', '<b>FOLFOX4 + Bevacizumab</b>', '<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV <b>AND</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours, <br><b>Bevacizumab</b> 5 mg/kg IV.<br><b>Day 2</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, day 2, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days <br> Repeat every 14 days', 'Moderate', 'Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. $J Clin Oncol. 2008;26(18)2013-2019.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Bevacizumab : Avastin<br>Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (63, 4, 'FOLFOX4 + panitumumab ', '<b>FOLFOX4 + panitumumab</b> ', '<b>Panitumumab</b> 6 mg/kg IV over 60 minutes <br> <b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV, day 1<br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV on day 1<br> <b>FOLLOWED BY Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>FOLLOWED BY Fluorouracil</b> 600mg/m<sup>2</sup> IV infusion over 22 hours on days 1 and 2<br> Repeat cycle every 14 days', 'Moderate', 'Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. $J Clin Oncol. 2010;28(31):4697-4705.$', '<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>', 'Fluorouracil : 5-FU<br>Oxaliplatin : Eloxatin, Oxaliplatin, various');
